The head of the U.S. Centers for Disease Control and Prevention said on Feb. 26 that a recent decline in COVID-19 cases may be stalling, a development she described as concerning while urging that safeguards to fight the virus remain in place.
The head of the U.S. Centers for Disease Control and Prevention said on Feb. 14 it is “absolutely” too soon to lift mask mandates, citing daily Covid-19 case numbers that despite recent declines remain more than double the levels seen the summer of 2020.
New cases of Covid-19 in the United States fell for a third week in a row, the first time the country saw such an extended decline since last September, though more than a million people are still being infected every week.
Six states reported record numbers of hospitalized Covid-19 patients, including Wisconsin, where officials issued a new order limiting the size of indoor public gatherings.
Nine U.S. states reported record increases in Covid-19 cases over the last seven days, mostly in the upper Midwest and West where chilly weather is forcing more activities indoors.
The number of tests coming back positive for Covid-19 is topping 25% in several states in the U.S. Midwest as cases and hospitalizations also surge in the region, according to a Reuters analysis.
Seven U.S. states reported record one-day increases in Covid-19 cases so far in September even as the average daily number of new infections is falling nationally.
Another wave of states prepared to ease coronavirus restrictions on U.S. commerce this week, despite health experts warning there is still too little diagnostic testing, while the White House forecast a staggering jump in the nation’s monthly jobless rate.
Better-than-expected social distancing practices have led an influential research model to lower the projected U.S. coronavirus death toll by 12 percent, while predicting some states may be able to safely begin easing restrictions as early as May 4.
GlaxoSmithKline is investing heavily in a Montana manufacturing facility that specializes in the manufacture of the company’s two-year-old shingles vaccine Shingrix, which is eying blockbuster status.